Lorus shares up 18% on Virulizin trial results; firm scouting research partner

TORONTO (CP) - Lorus Therapeutics Inc. (TSX:LOR) is in talks with many potential partners that could help fund more clinical trials of its Virulizin treatment for pancreatic cancer, its chief executive said Wednesday....More